The diabetes drug liraglutide ameliorates aberrant insulin receptor localisation and signalling in parallel with decreasing both amyloid-β plaque and glial pathology in a mouse model of Alzheimer's disease.
about
Alzheimer's disease and type 2 diabetes: multiple mechanisms contribute to interactionsNew drug treatments show neuroprotective effects in Alzheimer's and Parkinson's diseasesBrain insulin resistance in Alzheimer's disease and its potential treatment with GLP-1 analogsGut-brain connection: The neuroprotective effects of the anti-diabetic drug liraglutideThe nature, significance, and glucagon-like peptide-1 analog treatment of brain insulin resistance in Alzheimer's disease.Incretin mimetics as pharmacologic tools to elucidate and as a new drug strategy to treat traumatic brain injuryInsulin resistance in Alzheimer's disease.Deterioration of plasticity and metabolic homeostasis in the brain of the UCD-T2DM rat model of naturally occurring type-2 diabetesLong-Term Treatment with Liraglutide, a Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist, Has No Effect on β-Amyloid Plaque Load in Two Transgenic APP/PS1 Mouse Models of Alzheimer's Disease.The Ames dwarf mutation attenuates Alzheimer's disease phenotype of APP/PS1 mice.Insulin as a Bridge between Type 2 Diabetes and Alzheimer Disease - How Anti-Diabetics Could be a Solution for Dementia.Activation of mTOR: a culprit of Alzheimer's disease?Central insulin dysregulation and energy dyshomeostasis in two mouse models of Alzheimer's disease.Modulation of GLP-1 signaling as a novel therapeutic approach in the treatment of Alzheimer's disease pathology.The neuronal insulin receptor in its environment.Insulin Resistance and Neurodegeneration: Progress Towards the Development of New Therapeutics for Alzheimer's Disease.Exendin-4 protects Aβ(1-42) oligomer-induced PC12 cell apoptosis.Streptozotocin induced Alzheimer's disease like changes and the underlying neural degeneration and regeneration mechanism.Diabesity and Brain Energy Metabolism: The Case of Alzheimer's Disease.The GLP-1 Receptor Agonist Liraglutide Improves Memory Function and Increases Hippocampal CA1 Neuronal Numbers in a Senescence-Accelerated Mouse Model of Alzheimer's Disease.Neuroprotective astrocyte-derived insulin/insulin-like growth factor 1 stimulates endocytic processing and extracellular release of neuron-bound Aβ oligomers.Curcumin regulates insulin pathways and glucose metabolism in the brains of APPswe/PS1dE9 mice.Brain-Defective Insulin Signaling Is Associated to Late Cognitive Impairment in Post-Septic Mice.Linagliptin, a Dipeptidyl Peptidase-4 Inhibitor, Mitigates Cognitive Deficits and Pathology in the 3xTg-AD Mouse Model of Alzheimer's Disease.The diabetes drug liraglutide reverses cognitive impairment in mice and attenuates insulin receptor and synaptic pathology in a non-human primate model of Alzheimer's disease.
P2860
Q26864965-B7FFFCD3-3312-4DF3-90C4-3F770BA33BF0Q26866194-62626D1E-57F4-435D-84BE-98F5C3B1D934Q27012801-BF807DF5-AE93-4D41-BB20-368127753AFFQ28081671-78D9D56C-BE33-4EEB-BA9F-E6522036EFE6Q33600053-50F36133-1358-4B1F-98DC-999144012E60Q34362412-095E6E00-1270-4981-91B0-A2E738EFF4A8Q34622157-5E59C197-DAB6-4B6B-B59B-EC7E70FA71CEQ35213829-7CFB9CD8-5097-4A34-90B1-856EE6D4C8D7Q36078803-7C143244-F6DF-4728-BD4E-186596CC91D8Q36686413-657D5269-D35A-4C80-A956-E8502AFF5354Q38234927-9E354F65-9093-4E73-B65C-2E85E1BAEC74Q38443497-7839BBF4-DA3B-42CA-B7EE-45CF8D725B0CQ38688226-9341F358-D229-4592-8C03-3D4C59B73145Q38974881-8872C2E6-5F8F-4E4A-935C-0431E7734191Q39021127-D3C22B00-BD2B-4318-92B2-CBC211466795Q39042377-FCC34C81-1ED6-41A3-A5F9-7C24C08F4091Q41003546-CAAC5309-C2ED-40E1-BFFC-FACF8C6A0EAFQ41771769-61BF06E6-C7B1-4379-9F60-DEC290A789A8Q41995767-2F8B79C5-6E3C-4055-ACD0-4B5904575710Q42125458-9D10ECB8-A700-4711-8CF4-8E34E72103A4Q47120381-7CE6DFC5-B104-49DE-AEEE-40D68FD260B2Q48339072-800E711F-7398-4E73-9AD6-B69A6CC27E93Q48396253-F3973480-B1C8-4172-A38F-459794DD5F8CQ48488584-0B185EB7-0919-479F-903B-F2FB3A5D4F89Q50050282-1162E3D8-E2F3-43DF-AB7A-C6455FFF7087
P2860
The diabetes drug liraglutide ameliorates aberrant insulin receptor localisation and signalling in parallel with decreasing both amyloid-β plaque and glial pathology in a mouse model of Alzheimer's disease.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
The diabetes drug liraglutide ...... model of Alzheimer's disease.
@en
The diabetes drug liraglutide ...... model of Alzheimer's disease.
@nl
type
label
The diabetes drug liraglutide ...... model of Alzheimer's disease.
@en
The diabetes drug liraglutide ...... model of Alzheimer's disease.
@nl
prefLabel
The diabetes drug liraglutide ...... model of Alzheimer's disease.
@en
The diabetes drug liraglutide ...... model of Alzheimer's disease.
@nl
P2093
P2860
P50
P1476
The diabetes drug liraglutide ...... e model of Alzheimer's disease
@en
P2093
Caitriona M Long-Smith
Domhnall J O'Halloran
Paula L McClean
Sean Manning
P2860
P2888
P304
P356
10.1007/S12017-012-8199-5
P577
2012-09-21T00:00:00Z